tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Mangoceuticals Terminates Agreement with Navy Wharf

Story Highlights
Mangoceuticals Terminates Agreement with Navy Wharf

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Mangoceuticals, Inc. ( (MGRX) ).

On March 24, 2025, Mangoceuticals, Inc. entered into an agreement with Navy Wharf for exclusive licensing rights to a nutraceutical product. However, on July 30, 2025, both parties agreed to terminate the agreement without incurring material penalties, and Navy Wharf canceled all previously issued shares. Additionally, on July 29, 2025, a warrant holder exercised options to purchase 198,000 shares of common stock, raising $297,000.

More about Mangoceuticals, Inc.

Mangoceuticals, Inc. operates in the nutraceutical industry, focusing on products designed to manage blood glucose and Hemoglobin A1c levels, marketed under the brand Diabetinol® in the United States and Canada.

Average Trading Volume: 170,733

Technical Sentiment Signal: Sell

Current Market Cap: $18.2M

Find detailed analytics on MGRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1